Edwards Lifesciences Corp. has launched a 30-patient single-arm study of its next-generation Sapien 3 Ultra balloon-expandable transcatheter aortic valve system, which will push the expected European launch of the system to later in 2018.
In its Feb. 1 fourth-quarter 2017 earnings call, Edwards predicted that the Sapien 3 Ultra, which has a taller outer valve-skirt than the market-leading Sapien 3 valve, would earn a CE mark in the first quarter of 2018 and enter the US market by the end of the year. On March 21, Edwards announced it is projecting the system will reach both Europe and the US later in 2018
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?